Literature DB >> 27556665

Practical Issues for Retroperitoneal Sarcoma.

Vicky Pham1, Evita Henderson-Jackson, Matthew P Doepker, Jamie T Caracciolo, Ricardo J Gonzalez, Mihaela Druta, Yi Ding, Marilyn M Bui.   

Abstract

BACKGROUND: Retroperitoneal sarcoma is rare. Using initial specimens on biopsy, a definitive diagnosis of histological subtypes is ideal but not always achievable.
METHODS: A retrospective institutional review was performed for all cases of adult retroperitoneal sarcoma from 1996 to 2015. A review of the literature was also performed related to the distribution of retroperitoneal sarcoma subtypes. A meta-analysis was performed.
RESULTS: Liposarcoma is the most common subtype (45%), followed by leiomyosarcoma (21%), not otherwise specified (8%), and undifferentiated pleomorphic sarcoma (6%) by literature review. Data from Moffitt Cancer Center demonstrate the same general distribution for subtypes of retroperitoneal sarcoma. A pathology-based algorithm for the diagnosis of retroperitoneal sarcoma is illustrated, and common pitfalls in the pathology of retroperitoneal sarcoma are discussed.
CONCLUSIONS: An informative diagnosis of retroperitoneal sarcoma via specimens on biopsy is achievable and meaningful to guide effective therapy. A practical and multidisciplinary algorithm focused on the histopathology is helpful for the management of retroperitoneal sarcoma.

Entities:  

Mesh:

Year:  2016        PMID: 27556665     DOI: 10.1177/107327481602300308

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  2 in total

1.  Embryonal Rhabdomyosarcoma Presenting as Lung Metastasis in an Adult: An Uncommon Presentation.

Authors:  Rabia Taseer; Tabeer T Ahmed
Journal:  Cureus       Date:  2021-02-24

2.  Hyper-accuracy three-dimensional reconstruction as a tool for better planning of retroperitoneal liposarcoma resection: A case report.

Authors:  Mu-Shi Ye; Hao-Kai Wu; Xing-Zhang Qin; Fan Luo; Zhuo Li
Journal:  World J Clin Cases       Date:  2022-01-07       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.